mektovi
pierre fabre medicament - binimetinib - melanoma - antineoplastische middelen - binimetinib in combinatie met encorafenib is geïndiceerd voor de behandeling van volwassen patiënten met inoperabele of gemetastaseerde melanoom met een braf v600-mutatie.
braftovi
pierre fabre medicament - encorafenib - melanoma; colorectal neoplasms - antineoplastische middelen - encorafenib is indicated:in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutationin combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, who have received prior systemic therapy.
sunitinib krka 12.5 mg harde caps.
krka d.d. novo mesto d.d. - sunitinibmalaat 16,71 mg - eq. sunitinib 12,5 mg - capsule, hard - 12,5 mg - sunitinibmalaat 16.71 mg - sunitinib
sunitinib krka 25 mg harde caps.
krka d.d. novo mesto d.d. - sunitinibmalaat 33,41 mg - eq. sunitinib 25 mg - capsule, hard - 25 mg - sunitinibmalaat 33.41 mg - sunitinib
sunitinib krka 50 mg harde caps.
krka d.d. novo mesto d.d. - sunitinibmalaat 66,83 mg - eq. sunitinib 50 mg - capsule, hard - 50 mg - sunitinibmalaat 66.83 mg - sunitinib
sunitinib teva 12.5 mg harde caps.
teva b.v. - sunitinib 12,5 mg - capsule, hard - 12,5 mg - sunitinib 12.5 mg - sunitinib
sunitinib teva 25 mg harde caps.
teva b.v. - sunitinib 25 mg - capsule, hard - 25 mg - sunitinib 25 mg - sunitinib
sunitinib teva 37.5 mg harde caps.
teva b.v. - sunitinib 37,5 mg - capsule, hard - 37,5 mg - sunitinib 37.5 mg - sunitinib
sunitinib teva 50 mg harde caps.
teva b.v. - sunitinib 50 mg - capsule, hard - 50 mg - sunitinib 50 mg - sunitinib
sunitinib sandoz 12.5 mg harde caps.
sandoz sa-nv - sunitinib 12,5 mg - capsule, hard - 12,5 mg - sunitinib 12.5 mg - sunitinib